Nasdaq · Healthcare
Xilio Therapeutics, Inc. (XLO)
As-reported financials and recent SEC filings for Xilio Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$43.8M
Net income
$-35.0M
Net margin
-80.1%
Diluted EPS
$-4.19
ROE
-99.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-42.0M | $-60.6M | $-79.1M | $-89.1M | $-75.0M |
| Net income | $-35.0M | $-58.2M | $-76.4M | $-88.2M | $-75.8M |
| Diluted EPS | $-4.19 | $-7.62 | $-9.73 | $-11.27 | $-9.46 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →8-K2026-06-12
View on EDGAR →Largest Healthcare peers
Go deeper on XLO
Search Xilio Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.